Zimmer Biomet raises 2026 guidance as second-quarter net sales rise 4.8% to $2.177 billion
Zimmer Biomet reported second-quarter 2026 net sales of $2.177 billion, up 4.8% from the prior year, and diluted earnings per share of $1.03, up 33.8%. The company raised its full-year 2026 reported revenue and adjusted diluted EPS guidance, and adjusted EPS for the quarter was flat at $2.07.
Key points
- Q2 net sales of $2.177 billion rose 4.8% reported and 4.0% on an organic constant currency basis.
- Q2 diluted EPS was $1.03, up 33.8%; adjusted diluted EPS was $2.07, consistent with the prior year period.
- 2026 reported revenue change guidance raised to 3.9% to 4.9% from 2.5% to 4.5%; adjusted diluted EPS guidance raised to $8.47 to $8.59 from $8.40 to $8.55.
- Share repurchase expectation increased to up to $1 billion of common stock during fiscal year 2026.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:42 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.